Adalimumab Biosimilar Efficacy and Safety in a 5-Year-Old Patient with Severe Plaque Psoriasis During SARS-CoV-2 Pandemic Outbreak
Open Access Macedonian Journal of Medical Sciences
; 10(C):257-260, 2022.
Article
in English
| EMBASE | ID: covidwho-2066672
ABSTRACT
BACKGROUND:
Psoriasis is a chronic inflammatory disease that affects 2% of population. About 0.5–2% of psoriatic cases develop during pediatric age. In most cases, the condition is responsive to topical treatment. However, a small percentage of children require systemic treatment with conventional systemic drugs or biological agents, such as anti-tumor necrosis factor (TNF)-α. Adalimumab (ADA) is an anti-TNF-α recently approved for pediatric psoriasis in the European Union (from 4 years of age, 2015). CASE PRESENTATION We describe our experience treating a 5-year-old female patient affected by severe plaque psoriasis with ADA biosimilar during SARS-CoV-2 pandemic outbreak also using teledermatology.CONCLUSION:
The case reported in this article highlights the safety and the effectiveness of ADA biosimilar MSB11022 (Idacio®) in the treatment of a 5-year-old female affected by plaque psoriasis and paves the way to bigger trials for a more extensive use of TNF-α inhibitor biosimilars for psoriasis in pediatric population.
article; case report; child; clinical article; clinical trial; coronavirus disease 2019; drug safety; drug therapy; European Union; female; human; nonhuman; pandemic; pediatric dermatology; preschool child; psoriasis; psoriasis vulgaris; Severe acute respiratory syndrome coronavirus 2; systemic therapy; teledermatology; topical treatment; adalimumab; biosimilar agent; endogenous compound; tumor necrosis factor; tumor necrosis factor antibody; tumor necrosis factor inhibitor
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Open Access Macedonian Journal of Medical Sciences
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS